Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial

John P. Leonard; Marek Trneny; Huilai Zhang; Grzegorz S. Nowakowski; Koji Izutsu; Nathan Fowler; Catherine Thieblemont; Pier Luigi Zinzani; Argyrios Gkasiamis; Jung Ryun Ahn; John G. Gribben

doi:10.1200/jco-26-01085

Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial

J John P. Leonard (Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY) M Marek Trneny H Huilai Zhang G Grzegorz S. Nowakowski K Koji Izutsu (National Cancer Center Hospital, Tokyo, Japan) N Nathan Fowler (39Department of Hematology and Oncology, MD Anderson Cancer Center, Houston, TX) C Catherine Thieblemont (15Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Hémato-Oncologie and Université Paris Cité, Paris, France) P Pier Luigi Zinzani (12IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy) A Argyrios Gkasiamis (37Bristol Myers Squibb, Boudry, Switzerland) J Jung Ryun Ahn J John G. Gribben (6Barts Cancer Institute, Queen Mary University of London, London, United Kingdom)

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Journal of Clinical Oncology

Volume / Issue Vol. 44, Issue 17

Published June 10, 2026

Pages 1655-1655

DOI 10.1200/jco-26-01085

ISSN 0732-183X

Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

J

John P. Leonard

Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY

M

Marek Trneny

H

Huilai Zhang

G

Grzegorz S. Nowakowski

K

Koji Izutsu

National Cancer Center Hospital, Tokyo, Japan

N

Nathan Fowler

39Department of Hematology and Oncology, MD Anderson Cancer Center, Houston, TX

C

Catherine Thieblemont

15Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Hémato-Oncologie and Université Paris Cité, Paris, France

P

Pier Luigi Zinzani

12IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy

A

Argyrios Gkasiamis

37Bristol Myers Squibb, Boudry, Switzerland

J

Jung Ryun Ahn

J

John G. Gribben

6Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial

Article Details

Journal Info

Authors (11)

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer